Dupilumab is a novel treatment in development and trial to treat chronic eczema, which causes intense itching of the skin causing red spots and severe lesions. The creators of this drug seek Dupilumab to relieve extreme itching and the appearance of lesions.
This therapy is given through injections and interferes with the activities of proteins that produce the inflammatory processes and itching that promote eczema. Recent research has shown that Dupilumab is very effective and quickly provides great relief to patients suffering from this disease.
There is currently no medication that is used to control this disease, so Dupilumab is the ideal candidate to improve the quality of life of patients with eczema. This chronic disease affects approximately 20% of children and 10% of adults in the world, making it very common.
What sets Dupilumab apart from other treatments is that it targets the proteins interlucin-4 and interlucin-13 that are the cause of inflammation.
During studies of patients with eczema, 40% who were treated with Dupilumab saw considerable improvements in their skin lesions compared to the other 7% who only took placebo.
In the final study, all participating patients were treated with the drug and topical creams, experiencing a decrease of more than 60% in the severity of the disease, which shows a triumph for Dupilumab as a drug against eczema.
